European Commission approves ebola vaccine regimen for the prevention of ebola virus disease caused by Zaire ebolavirus species in individuals aged one year and above

Two marketing applications were submitted, making up a 2 dose regimen, with 1st dose using Zabdeno (Ad26.ZEBOV), based on Janssen’s AdVac viral vector technology and 2nd dose, administered ~ 8 weeks later, with Mvabea (MVA-BN-Filo), based on Bavarian Nordic’s MVA-BN technology.